Akebia Therapeutics Stock Fundamentals
| AX9 Stock | 0.88 1.05 54.40% |
Akebia Therapeutics fundamentals help investors to digest information that contributes to Akebia Therapeutics' financial success or failures. It also enables traders to predict the movement of Akebia Stock. The fundamental analysis module provides a way to measure Akebia Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Akebia Therapeutics stock.
Akebia |
Akebia Therapeutics Company EBITDA Analysis
Akebia Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Akebia Therapeutics EBITDA | (227.35 M) |
Most of Akebia Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Akebia Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Akebia Therapeutics reported earnings before interest,tax, depreciation and amortization of (227.35 Million). This is much lower than that of the sector and significantly lower than that of the EBITDA industry. The ebitda for all Germany stocks is notably higher than that of the company.
Akebia Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Akebia Therapeutics's current stock value. Our valuation model uses many indicators to compare Akebia Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Akebia Therapeutics competition to find correlations between indicators driving Akebia Therapeutics's intrinsic value. More Info.Akebia Therapeutics is rated below average in current valuation category among its peers. It is rated third in price to book category among its peers . The ratio of Current Valuation to Price To Book for Akebia Therapeutics is about 3,141,366 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Akebia Therapeutics' earnings, one of the primary drivers of an investment's value.Akebia EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Akebia Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Akebia Therapeutics could also be used in its relative valuation, which is a method of valuing Akebia Therapeutics by comparing valuation metrics of similar companies.Akebia Therapeutics is currently under evaluation in ebitda category among its peers.
Akebia Fundamentals
| Current Valuation | 12.46 M | |||
| Price To Book | 3.97 X | |||
| Price To Sales | 0.18 X | |||
| Revenue | 213.58 M | |||
| EBITDA | (227.35 M) | |||
| Net Income | (282.84 M) | |||
| Cash Flow From Operations | (252.97 M) | |||
| Market Capitalization | 387.3 M | |||
| Total Asset | 525.55 M | |||
| Net Asset | 525.55 M |
About Akebia Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Akebia Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akebia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akebia Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Akebia Stock Analysis
When running Akebia Therapeutics' price analysis, check to measure Akebia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Therapeutics is operating at the current time. Most of Akebia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akebia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Therapeutics' price. Additionally, you may evaluate how the addition of Akebia Therapeutics to your portfolios can decrease your overall portfolio volatility.